Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Potash Corporation of Saskatchewan Inc.’s ( POT - Analyst Report ) second-quarter 2012 adjusted (excluding one-time items) earnings of $1.01 per share missed the Zacks Consensus Estimate by a penny.
Including one-time items, earnings came in at 60 cents per share compared with 96 cents a year ago. The company recorded a charge of $341 million (or 39 cents a share) on its investment in Sinofert Holdings Limited and $29 million (or 2 cents a share) related to its phosphate segment, which brought down its earnings.
Sales in the quarter came in at $2,396 million, up 3.1% from $2,325 million a year ago, beating the Zacks Consensus Estimate of $2,378 million. The growth was aided by increased potash demand.
Segment Review
Potash: Sales volumes of 2.6 million tons in the quarter were up from 2.5 million tons in the year-ago quarter. Production costs increased in the quarter, but were offset by rising prices. This has led to a 1% rise in gross margin to $801 million in the quarter. Average realized potash price was $433 per ton, up 4% from the prior-year quarter.
Phosphate: Sales volumes declined 10% over the prior-year quarter to 0.9 million tons due to lower production and timing of vessel loadings. Weak sales in North America were offset by higher offshore sales coupled with strong feed and industrial volumes. Gross margins came down 42.2% to $96 million, due to lower sales volumes and prices for fertilizer products. Average realized phosphate price was $552 per ton, down 4.5% year over year.
Nitrogen:Sales volumes for the segment was almost flat versus the prior-year quarter at 1.3 million tons driven by higher realized prices. Gross margin increased significantly by 44.5% to $302 million in the reported quarter. Average realized prices for nitrogen products rose 9% to $436 per ton.
Financial
Cash and cash equivalent amounted to $491 million as of June 30, 2012, versus $430 million as of December 31, 2011. Long-term debt stood at $3,464 million as of June 30, 2012, compared with $3,705 million as of December 31, 2011.
Outlook
The company reduced its earnings forecast for 2012to $2.80 to $3.20 per share from its previous expectation of $3.20 to $3.60 per share to reflect the impact of an impairment charge that hurt its second quarter results. Potash expects third quarter earnings to be in the range of 70 cents to 90 cents a share.
The company expects gross profits from its potash business in 2012 to be in the range of $2.6 billion to $2.8 billion. The company expects production costs to be higher and realizations lower in the second half of 2012.
Potash expects phosphate margins to improve in the second half of 2012 driven by tight global supply and strong demand in the U.S. and Latin America. The company expects combined phosphate and nitrogen gross margin for 2012 to be in the range of $1.4 billion to $1.6 billion.
For 2012, Potash expects capital expenditures (excluding capitalized interest and major repairs and maintenance) to be $2.2 billion.
Potash Corp. competes with BASF SE ( BASFY ) and Mosaic Co. ( MOS - Snapshot Report ) . The company retains a Zacks #3 Rank, reflecting a short-term (1 to 3 months) Hold rating. Currently, we have a long-term (more than 6 months) Neutral recommendation on the stock.
Read the full Analyst Report on POT
Read the full on BASFY
Read the full Snapshot Report on MOS